13-16 Panel Cups | Collection

13 to 16 Panel Drug Test Cups

Drug test cups from 13-panel through 16-panel available from $1.59 per cup, representing the tier where fentanyl first appears as a standard integrated strip in every configuration, EDDP (methadone metabolite verification) becomes available for clinical MAT monitoring, and NFYL NorFentanyl) provides extended fentanyl detection to 96 hours. Every cup in this range includes a built-in temperature strip, a no-drip lid, 120mL or 90mL capacity, and 99% accuracy in a 5-minute result window. CLIA Waived and FDA approved configurations are available at the 13, 14, 15, and 16 panel count. Forensic Use Only configurations with ETG, TRA, K2, KRA, and ADLTX specialty additions are available at each tier. Searching for a 13 panel drug test cup near me or a 16 panel drug test cup near me? 12 Panel Now ships same-day wholesale before 3:00 PM EST anywhere in the US with free shipping on qualifying bulk orders. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now produces all 13 through 16 panel cups to the same quality and antibody standards applied across the full product range.

What Does a 13 Panel Drug Test Cup Test For?

A 13 panel drug test cup tests for thirteen substances and is the minimum panel count at 12 Panel Now where Fentanyl appears as a standard integrated strip in every configuration, making it the lowest-cost cup format compliant with the post-July 2025 HHS fentanyl authorization mandate as specified in the Federal Register. The defining clinical feature of the 13-panel tier over the 12-panel cup is that FEN is the standard thirteenth strip on every 13-panel cup in the Serenity lineup, regardless of whether the configuration is CLIA Waived or FUO. At 12 Panel Now, the 13 panel drug test cup is available in three primary configurations. The CLIA Waived SM-CDOA-4135CLIA with FEN at 1 ng/mL is the most sensitive clinical fentanyl screening cup in this range. The FUO 90mL ETG+FEN+TRA (SM-CDOA-8135-FUO-90) adds alcohol and tramadol detection alongside the standard baseline. The FUO GAB+ETG+FEN configuration (SM-CDOA-5135FUO) adds Gabapentin and Ethyl Glucuronide alongside fentanyl. The HHS Federal Register mandate of January 2025 authorizes fentanyl as a standard testing analyte on federal workplace testing panels effective July 7, 2025, making the 13-panel the natural compliance upgrade from the standard 12-panel for all regulated programs. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now produces all 13 through 16 panel cups to the same quality standards applied across the full product range.

What Is the Difference Between the 13 Panel CLIA Waived Cup and the 13 Panel FUO Cup?

The 13 Panel CLIA Waived cup (SM-CDOA-4135CLIA) and the 13 Panel FUO cups differ in three important ways beyond classification. First, the CLIA Waived cup runs FEN at 1 ng/mL (FEN 1 ng/mL ultra-low threshold) rather than the standard 20 ng/mL used on the FUO configurations, making it significantly more sensitive to fentanyl at micro-concentrations encountered in clinical monitoring. Second, the CLIA Waived cup uses lower cutoff thresholds across all analytes: AMP/500 versus standard 1000, COC/150 versus standard 300, MET/500 versus standard 1000. These lower cutoffs increase analytical sensitivity for clinical monitoring where early detection of prescription non-compliance or low-concentration exposure is the primary goal. Third, only the CLIA Waived configuration is authorized for use in clinical settings under CLIA jurisdiction. The FUO ETG+FEN+TRA 90mL and the FUO GAB+ETG+FEN configurations are appropriate for forensic, compliance, probation, correctional, and employer contexts. For a complete explanation of the CLIA Waived vs FUO classification difference, see the CLIA Waived drug test verification guide at 12 Panel Now. The full range of CLIA Waived cup configurations from 5 through 16 panels is available at the CLIA Waived drug test cups collection.

What Is EDDP on a Drug Test and Why Does the 14 Panel Cup Include It?

What is EDDP on a drug test? EDDP stands for 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, the primary urinary metabolite of methadone, and its presence on the 14 Panel CLIA Waived Drug Test Cup (SM-CDOA-9145CLIA) transforms methadone monitoring from a simple compliance check into a physiologically validated specimen integrity test: a urine sample that tests MTD EDDP methadone-positive but EDDP-negative is physiologically inconsistent with genuine methadone ingestion and indicates specimen adulteration or substitution rather than actual methadone use. When a patient takes methadone, the liver metabolizes it to EDDP, which is excreted in urine alongside the parent MTD compound. Both should be present simultaneously in a genuine specimen from a patient who is actually taking methadone. If a specimen tests positive for methadone but negative for EDDP, it suggests that methadone was added directly to the specimen container after collection, a common form of specimen adulteration in methadone monitoring programs where patients know they will be tested for methadone compliance. The NIH pharmacology documentation on methadone metabolism confirms that EDDP is the primary metabolite produced during hepatic methadone clearance and should be present in urine alongside any detectable MTD concentration following genuine ingestion. For methadone treatment programs that have experienced specimen adulteration events, the EDDP strip on the 14-panel CLIA Waived cup is the only point-of-care method for detecting this form of tampering at the time of collection. The SAMHSA Medication-Assisted Treatment guidelines document specimen adulteration as a documented compliance monitoring challenge in methadone treatment programs, reinforcing the clinical value of the EDDP strip as a specimen integrity tool within the 14-panel CLIA Waived cup.

What Does the 14 Panel CLIA Waived Cup Test For?

The 14 Panel CLIA Waived Drug Test Cup (SM-CDOA-9145CLIA) from $1.79 screens for: Amphetamines (AMP/500 ng/mL), Barbiturates (BAR/300 ng/mL), Buprenorphine (BUP/10 ng/mL), Benzodiazepines (BZO/300 ng/mL), Cocaine (COC/150 ng/mL), EDDP (EDDP/300 ng/mL), Fentanyl (FEN/1 ng/mL), MDMA (MDMA/500 ng/mL), Methamphetamine (MET/500 ng/mL), Morphine/Opiates (MOR/300 ng/mL), Methadone (MTD/300 ng/mL), Oxycodone (OXY/100 ng/mL), Tricyclic Antidepressants (TCA/1000 ng/mL), and THC (THC/50 ng/mL). Like the CLIA Waived 13-panel, this cup uses lower analytical cutoff levels across all analytes than the FUO configurations, providing higher sensitivity for clinical monitoring environments. All presumptive positive results must be confirmed by GC-MS or LC-MS/MS laboratory testing before any clinical action is taken, consistent with SAMHSA confirmation requirements.

What Is NorFentanyl on a Drug Test and Why Does the 15 Panel Cup Include It?

NorFentanyl drug test strip (NFYL) detects the primary urinary metabolite of fentanyl, produced when the liver demethylates fentanyl via CYP3A4 enzymes, and its presence on the 15 Panel CLIA Waived Drug Test Cup (SM-CDOA-9155CLIA) at 5 ng/mL extends the total fentanyl detection window from 72 hours with the parent FEN strip alone to up to 96 hours when both FEN and NFYL strips are running simultaneously. Fentanyl is eliminated from the body primarily as norfentanyl, which is excreted in urine in concentrations approximately 5 to 10 times higher than the parent fentanyl compound. Because norfentanyl persists in urine longer than fentanyl itself, the NFYL strip at 5 ng/mL on the 15-panel CLIA Waived cup detects fentanyl exposure up to 96 hours after the last use when the parent FEN concentration has already dropped below the detection threshold of the FEN strip. For programs that test on weekly or semi-weekly schedules, the NFYL strip closes the time gap between monitoring appointments where fentanyl exposure could otherwise go undetected. The NIH research on fentanyl pharmacokinetics and urinary detection confirms that norfentanyl is the primary urinary marker for fentanyl exposure with a longer detection window than the parent compound, making NFYL the preferred marker for retrospective fentanyl monitoring in programs with scheduled appointment intervals. For buprenorphine programs and pain management clinics where patients need monitoring for illicit fentanyl exposure between monthly appointments, the 15-panel CLIA Waived cup with NFYL provides the widest available fentanyl detection window in a CLIA Waived format at $1.59 per cup.

How Does the 15 Panel Drug Test Cup Differ from the 14 Panel Drug Test Cup?

The 15 Panel CLIA Waived Drug Test Cup (SM-CDOA-9155CLIA) adds NorFentanyl (NFYL/5 ng/mL) to the 14-panel baseline’s FEN strip, creating dual fentanyl detection at both the parent compound level and the metabolite level simultaneously. The 14-panel CLIA Waived (SM-CDOA-9145CLIA) includes EDDP for methadone metabolite verification alongside FEN. The 15-panel CLIA Waived (SM-CDOA-9155CLIA) trades EDDP for NFYL, making it the appropriate choice for programs whose primary monitoring goal is extended fentanyl detection window coverage rather than methadone compliance verification. Programs that need both EDDP and NFYL simultaneously should contact 12 Panel Now at 561-897-9238 to discuss custom panel configurations combining both markers. For programs needing the EDDP methadone metabolite check alongside extended fentanyl detection, the 16 Panel CLIA Waived (SM-CDOA-7165CLIA) includes EDDP, NFYL, and FEN together in a single 16-panel CLIA Waived cup from $1.99. The relationship between the 13, 14, 15, and 16 panel CLIA Waived tiers is essentially a progression of fentanyl sensitivity and methadone metabolite verification capability, with each tier adding analytical depth to the same core substance baseline.

What Does a 16 Panel Drug Test Cup Test For?

A 16 panel drug test cup tests for sixteen substances and represents the highest panel count at 12 Panel Now with available CLIA Waived classification, with the CLIA Waived SM-CDOA-7165CLIA configuration combining FEN at 1 ng/mL, NFYL (NorFentanyl), EDDP (methadone metabolite), PPX (Propoxyphene), and TCA (Tricyclic Antidepressants) alongside the standard substance baseline in a single clinical-grade cup at $1.99. The 16-panel tier is where all three clinical specialty analytes introduced across the 13, 14, and 15 panel tiers converge: FEN for fentanyl detection, NFYL for extended fentanyl window coverage, and EDDP for methadone specimen integrity verification. The CLIA Waived 16-panel (SM-CDOA-7165CLIA) is the most analytically comprehensive CLIA Waived cup available at 12 Panel Now and is the appropriate format for methadone treatment programs that need simultaneous EDDP methadone metabolite verification and extended NFYL fentanyl detection alongside the complete clinical substance baseline. The FUO 16-panel configurations extend further into emerging-substance territory: the SM-CDOA-3165FUO adds TRA (Tramadol) and TCA for programs managing complex prescription analgesic monitoring, while the SM-CDOA-1165KAD3-FUO adds K2/Synthetic Cannabinoids and ADLTX specimen validity checking for comprehensive compliance and forensic settings. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now maintains full stock of all 16-panel configurations with no backorders. For programs that need analytes beyond 16 panels such as Gabapentin, Kratom, Ketamine, or Xylazine, see the 17 through 28 panel cup range.

What Is the Difference Between the 16 Panel CLIA Waived Cup and the 16 Panel FUO Cup?

The 16 Panel CLIA Waived (SM-CDOA-7165CLIA) and the 16 Panel FUO configurations differ in both classification and analyte selection. The CLIA Waived cup focuses on clinical analyte depth, adding NFYL, EDDP, PPX, and TCA alongside FEN at ultra-low cutoffs for maximum clinical sensitivity in physician office and treatment clinic settings. The FUO configurations focus on compliance and emerging-substance breadth: the SM-CDOA-3165FUO adds ETG alcohol detection and TRA tramadol detection alongside FEN for probation and compliance monitoring, while the SM-CDOA-1165KAD3-FUO adds K2/Synthetic Cannabinoids and ADLTX specimen validity strips for forensic and comprehensive compliance settings. Programs in clinical settings under CLIA jurisdiction should select the SM-CDOA-7165CLIA. Programs in forensic, compliance, employer, or correctional settings should select the FUO configuration that matches their specific analyte requirements. For programs transitioning from the 16-panel to higher analyte counts, the 17-panel format adds Gabapentin and Kratom alongside the standard fentanyl and alcohol baseline.

What Is Gabapentin (GAB) on the 13 Panel Drug Test Cup?

What is gabapentin on a drug test? GAB on the 13 Panel Drug Test Cup with Gabapentin (SM-CDOA-5135FUO) stands for Gabapentin, a prescription anticonvulsant and neuropathic pain medication that does not cross-react with any standard immunoassay strip on panels below 13, making the dedicated GAB strip at 1000 ng/mL on this configuration the only point-of-care method for detecting gabapentin at the cup format at the 13-panel tier. Gabapentin (Neurontin) and pregabalin (Lyrica) are prescribed for neuropathic pain, fibromyalgia, seizure disorders, and anxiety, and have documented misuse potential particularly in opioid-using populations where gabapentin potentiates opioid effects through calcium channel modulation. As documented for the 15-panel dip card with GAB, the gabapentin-opioid potentiation mechanism is most clinically significant in populations already enrolled in buprenorphine or methadone treatment. The SM-CDOA-5135FUO is the minimum cup format at 12 Panel Now that includes a dedicated GAB strip, making it the appropriate choice for pain management programs prescribing gabapentin alongside opioids, and for MAT programs in states that have scheduled gabapentin as a controlled substance and require compliance monitoring. The CDC overdose prevention documentation on polysubstance use identifies gabapentin co-use with opioids as a documented polysubstance risk pattern in treatment-engaged populations. All presumptive positive GAB results must be confirmed by GC-MS or LC-MS/MS before any consequential action is taken.